Anti-CD20 [B9E9]

Absolute Antibody

Anti-CD20 [B9E9]

7

This antibody has been used in western blot detection of CD20 in human plasma, revealing elevated CD20 levels in plasma from chronic lymphocytic leukemia patients (Manshouri et al, 2003). An scFv derived from this antibody fused to streptavidin has been investigated as a method of pretargeted radioimmunotherapy for lymphomas (Schultz et al, 2000), and has been demonstrated to be non-toxic in a phase I trial of non-Hodgkin lymphoma patients (Forero et al, 2004). Additionally, measles viruses engineered to express this scFv are able to enter CD20+ target cells through interaction with CD20 antigen, with clinical relevance for lymphoma therapy (Bucheit et al, 2003).

Western Blot

WB; radioimmunotherapy

Research Use Only

Monoclonal

B9E9

MS4A1

membrane spanning 4-domains A1

B1; B-lymphocyte antigen CD20; B-lymphocyte cell-surface antigen B1; Bp35; CD20; CD20 antigen; CD20 receptor; CVID5; FMC7; LEU-16; leukocyte surface antigen Leu-16; membrane-spanning 4-domains, subfamily A, member 1; S7

Human

IgG1

B-lymphocyte antigen CD20

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Human

This antibody was raised against human CD20.

-20°C,2°C to 8°C

12352203